IMM 4.41% 32.5¢ immutep limited

Ann: Immutep reports promising data from INSIGHT-003 trial, page-11

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 264 Posts.
    lightbulb Created with Sketch. 147
    The reports are well written without hyperbole
    Instead of writing significant improvement on triple therapy they wrote results compare favorably to the dual therapy registration trial.

    Instead of “compare favorably” I would written:
    Triple therapy breaks dual therapy historical records!!
    3 for 3!
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.